CN115298179A - Mettl3调节剂 - Google Patents

Mettl3调节剂 Download PDF

Info

Publication number
CN115298179A
CN115298179A CN202080088790.7A CN202080088790A CN115298179A CN 115298179 A CN115298179 A CN 115298179A CN 202080088790 A CN202080088790 A CN 202080088790A CN 115298179 A CN115298179 A CN 115298179A
Authority
CN
China
Prior art keywords
cycloalkyl
alkyl
compound
halogen
membered heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080088790.7A
Other languages
English (en)
Chinese (zh)
Inventor
T·A·韦恩
B·L·霍杜斯
P·A·博里阿克-斯霍丁
E·A·西克米尔
J·E·J·米尔斯
R·A·科普兰
B·A·斯帕林
M·H·丹尼尔斯
A·S·塔斯克
K·W·邓肯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exent Therapeutics
Original Assignee
Exent Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exent Therapeutics filed Critical Exent Therapeutics
Publication of CN115298179A publication Critical patent/CN115298179A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202080088790.7A 2019-10-21 2020-10-20 Mettl3调节剂 Pending CN115298179A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962923936P 2019-10-21 2019-10-21
US62/923,936 2019-10-21
PCT/IB2020/001135 WO2021079196A2 (en) 2019-10-21 2020-10-20 Mettl3 modulators

Publications (1)

Publication Number Publication Date
CN115298179A true CN115298179A (zh) 2022-11-04

Family

ID=73856560

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080088790.7A Pending CN115298179A (zh) 2019-10-21 2020-10-20 Mettl3调节剂

Country Status (6)

Country Link
US (1) US20230027361A1 (cg-RX-API-DMAC7.html)
EP (1) EP4048674A2 (cg-RX-API-DMAC7.html)
JP (1) JP2022553077A (cg-RX-API-DMAC7.html)
CN (1) CN115298179A (cg-RX-API-DMAC7.html)
AU (1) AU2020372002A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021079196A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115850280A (zh) * 2022-12-08 2023-03-28 南京康立瑞生物科技有限公司 一种抗病毒药恩替卡韦中间体n4的制备方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240101589A1 (en) * 2020-10-08 2024-03-28 Strom Therapeutics Limited Inhibitors of mettl3
CN113234079B (zh) * 2021-04-30 2022-02-01 上海湃隆生物科技有限公司 用作prmt5抑制剂的核苷类似物
CN114032311A (zh) * 2021-12-24 2022-02-11 山东大学齐鲁医院 Mettl3在aml化疗耐药性中的应用
WO2023151697A1 (zh) * 2022-02-11 2023-08-17 四川海思科制药有限公司 一种mettl3抑制剂及组合物及其在医药上的应用
EP4652163A1 (en) 2023-01-20 2025-11-26 Epics Therapeutics Piperidine derivatives as mettl3 inhibitors
JP2026514449A (ja) 2023-03-30 2026-05-11 ノヴァリックス 新規mettl3阻害剤及び治療におけるその使用
EP4770631A1 (en) * 2023-08-29 2026-07-08 Purdue Research Foundation Prodrugs of nicotinamide n-methyltransferase (nnmt) inhibitors and uses thereof
WO2025106014A1 (en) * 2023-11-14 2025-05-22 Engine Biosciences Pte. Ltd. Compounds and methods for pkmyt1 inhibition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI730980B (zh) * 2015-08-26 2021-06-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
WO2018065365A1 (en) * 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
MA49840A (fr) * 2017-08-09 2020-06-17 Prelude Therapeutics Inc Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)
AU2018381004B2 (en) * 2017-12-05 2021-04-29 Angex Pharmaceutical, Inc. Heterocyclic compounds as PRMT5 inhibitors
JP2022522534A (ja) * 2019-04-02 2022-04-19 アリゴス セラピューティクス インコーポレイテッド Prmt5を標的にする化合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115850280A (zh) * 2022-12-08 2023-03-28 南京康立瑞生物科技有限公司 一种抗病毒药恩替卡韦中间体n4的制备方法

Also Published As

Publication number Publication date
AU2020372002A1 (en) 2022-05-26
EP4048674A2 (en) 2022-08-31
WO2021079196A3 (en) 2021-07-01
JP2022553077A (ja) 2022-12-21
WO2021079196A9 (en) 2022-07-14
WO2021079196A2 (en) 2021-04-29
US20230027361A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
CN115368373B (zh) 螺环类化合物及其用途
EP3814357B1 (en) Heterocyclic and heteroaryl compounds for treating huntington's disease
CN111153901B (zh) 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途
ES2619125T3 (es) Compuestos heterocíclicos fusionados como inhibidores de proteína cinasa
AU2017250302B2 (en) Inhibitors of activin receptor-like kinase
EP2318408B1 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
WO2021079196A9 (en) Mettl3 modulators
KR102522832B1 (ko) 호흡기 세포융합 바이러스 (rsv)의 복제에 대하여 저해 활성을 갖는 피페리딘 치환된 피라졸로[1,5―a]피리미딘 유도체
US9956220B2 (en) Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitors
EP4129996A1 (en) Novel aminopyrimidine egfr inhibitor
CN115504980B (zh) 嘧啶并含氮六元芳香杂环类化合物及其用途
WO2013051639A1 (ja) ピラゾロキノリン誘導体
JP7219902B2 (ja) ブルトン型チロシンキナーゼ阻害剤
CN115279756A (zh) Mettl3调节剂
JP2016507502A (ja) カゼインキナーゼ1δ/ε阻害剤としての新規な置換イミダゾール
CN103582638A (zh) 杂芳基并嘧啶类衍生物、其制备方法和用途
TW202438054A (zh) 作為MTA-協同PRMT5抑制劑的5-胺基-6,8-二氫-1H-呋喃并[3,4-d]吡咯并[3,2-b]吡啶-2-甲醯胺衍生物
CA3249778A1 (en) HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF HUNTINGTON'S DISEASE
KR20240148322A (ko) 이작용성 아릴설폰아미드 화합물
CN119707931A (zh) 作为prmt5的mta协同抑制剂的1-(1-氧代-1,2-二氢酞嗪-6-基)环烷基-1-甲酰胺衍生物的中间体和合成方法
EP4011865A1 (en) Bridged heterocyclyl-substituted pyrimidine compound, preparation method therefor, and pharmaceutical use thereof
IL325314A (en) Tyk2 inhibitors, compositions and methods thereof
KR20240150419A (ko) 아릴설폰아미드 화합물
WO2023101895A1 (en) Fused pyrazole urea analogs as glucosylceramide synthase inhibitors
CN113880842A (zh) 取代的炔基杂环化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20221104